Back to mobile site

TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)

October 20, 2026 12:11 PM EDT Send to a Friend
TD Cowen analyst Kyle Boucher reiterated a Hold rating and $4.50 price target on Myriad ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login